Evidence map›Paper›PMID 41661353›Full record

ReviewJournal of materials science. Materials in medicine2026

Magnetic nanoparticles as promising materials for the future of medicine.

Fatemeh Najafi, Arezoo Maleki-Hajiagha, Nasim Kaveh Farsani, Majed Tavakkol, Akansha Sharma, Seyedeh Elaheh Sheykholeslami, Faranak Farahmand, Zahra Kazemi, Asal Katebi, Ahmad Reza Farmani and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fatemeh NajafiDepartment of Chemical Engineering, Pennsylvania State University, Pennsylvania, PA, USA.
Arezoo Maleki-HajiaghaDepartment of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Nasim Kaveh FarsaniDepartment of Chemical Engineering, Isfahan University of Technology, Isfahan, Iran.
Majed TavakkolBiotechnology Research Laboratory, School of Chemical, Petroleum and Gas Engineering, Iran University of Science and Technology, Tehran, Iran.
Akansha SharmaDepartment of Chemistry, Oklahoma State University, Stillwater, OK, USA.
Seyedeh Elaheh SheykholeslamiSchool of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
Faranak FarahmandDepartment of Molecular and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Zahra KazemiDepartment of Chemistry, Faculty of Basic Sciences, Arak University, Arak, Iran.
Asal KatebiDepartment of Immunology, Pasteur Institute of Iran, Tehran, Iran. A_katebi@pasteur.ac.ir.
Ahmad Reza FarmaniDepartment of Tissue Engineering, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. ahmadrezafarmani66@gmail.com.
Tamim ChalatiSchool of Science, Faculty of Engineering and Science, University of Greenwich, Kent, UK. T.Chalati@greenwich.ac.uk.ORCID http://orcid.org/0000-0002-4253-5754

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past few decades, magnetic nanoparticles (MNPs) have emerged as a focal point of research due to their versatility and diverse applications across biomedical and technological domains. The rapid advancement in nanotechnology has enabled MNPs to be utilized in drug delivery, magnetic resonance imaging (MRI), and cancer therapy. In biomedical applications, MNPs are valued for their small size, biocompatibility, and responsiveness to external magnetic fields, facilitating targeted drug delivery, cell tracking, and magnetic hyperthermia. MNPs can be functionalized with therapeutic agents for precision-targeted delivery and magneto-mechanical activation at the cellular level. This review explores the synthesis and characterization of MNPs, focusing on their therapeutic potential in cancer treatment. Iron oxide nanoparticles have been studied for their ability to target tumors through passive and active mechanisms, allowing controlled drug release within the tumor microenvironment. Coating MNPs with biocompatible materials enhances their stability and drug loading capacity while reducing toxicity. MNPs are also integrated with other nanotechnologies to create multifunctional theranostic platforms combining treatment and imaging capabilities. Despite promising preclinical results, clinical translation requires further optimization to address challenges like targeting efficiency and regulatory approval. Continued research and interdisciplinary collaboration are essential to fully realize the potential of MNPs in advancing precision medicine and improving patient outcomes.

Indexed as

Magnetite NanoparticlesAnimalsAntineoplastic AgentsBiocompatible MaterialsDrug Delivery SystemsHumansMagnetic Resonance ImagingNanotechnologyNeoplasmsTheranostic NanomedicineAntineoplastic AgentsBiocompatible MaterialsMagnetite Nanoparticles

Identifiers

PMID41661353
PMCPMC12894208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.